| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.1 | 0.04 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.076 | 0.05 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | -0.072 | 0.05 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.05 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | -0.072 | 0.05 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.096 | 0.05 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | -0.1 | 0.05 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.05 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.12 | 0.06 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.067 | 0.06 |